Bioserv Corporation

bioservamerica.com

Bioserv Corporation located in San Diego, California is a boutique cGMP contract manufacturing organization (CMO) serving the pharmaceutical, biotechnology, life sciences, medical device, and diagnostic industries since 1988. Bioserv’s core competency is manual filling which allows us to be very flexible and capable of handling small to medium batches effortlessly. Bioserv has a broad range of manufacturing suites to meet your production needs. Bioserv’s manufacturing facilities include certified Class 100,000 (Class 8 or Class D), Class 10,000 (Class 7 or Class C), Class 100 (Class 5 or Class A) areas, and Uncontrolled laboratory rooms. Whether a client is looking to move a drug product candidate into the pre-clinical setting, Phase I, Phase II clinic, or looking for basic reagent formulation and filling expertise, Bioserv has the experience and capabilities to get our clients there on time. We have filled a significant number of cGMP finished drug product lots for our clients to support their Phase I and Phase II clinical trial needs. We have a broad level of highly skilled production experts that have worked with very complex formulations, including liposomes, emulsions, nano-particles, small molecules, conjugates, and adjuvants.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

FRONTAGE ACQUIRES NUCRO-TECHNICS INC. AND NUCRO-TECHNICS HOLDINGS, INC.

PRNewswire | August 17, 2023

news image

Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc. Nucro-Technics is a pharmaceutical contract research organization that conducts analytical chemistry, microbiology, toxicology, bioanalytical, and stability sample storage and testing services. In addition, it provides consulting services, especially in quality control and assurance as well as in Natu...

Read More

Research

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

news image

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More

ANGELINI PHARMA, INC. U.S. LAUNCHES FIRST INFECTION PREVENTION PORTFOLIO

PR Newswire | February 03, 2020

news image

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products. HAIs continue to cause preventable complications and poor patient outcomes. HAIs cause more patient deaths every year than breast, prostate, and colorectal cancer. With Angelini's new portfolio, designed to be used across the care continuum, they are addressing the "why" behi...

Read More

Pharma Tech

LEO PHARMA AND VEEVA SYSTEMS PARTNER FOR DIGITAL PATIENT-CENTERED TRIALS

LEO Pharma | September 30, 2021

news image

LEO Pharma , a global leader in medical dermatology, and Veeva Systems announced a strategic technology partnership to enable scalable digital trials, paperless and patient-centered. Building on its success with the Veeva Clinical Operations suite, LEO Pharma will complete its standardization on existing Veeva clinical technology, be an early adopter of future Veeva solutions, and help shape the Veeva digital trials roadmap. By adopting technology and optimized business processes,...

Read More
news image

Pharmacy Market

FRONTAGE ACQUIRES NUCRO-TECHNICS INC. AND NUCRO-TECHNICS HOLDINGS, INC.

PRNewswire | August 17, 2023

Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc. Nucro-Technics is a pharmaceutical contract research organization that conducts analytical chemistry, microbiology, toxicology, bioanalytical, and stability sample storage and testing services. In addition, it provides consulting services, especially in quality control and assurance as well as in Natu...

Read More
news image

Research

EXSCIENTIA AND BRISTOL MYERS SQUIBB ENTER INTO A MULTI-TARGET, AI-DRIVEN DRUG DISCOVERY PARTNERSHIP

Exscientia, Bristol Myers Squibb | May 20, 2021

Exscientia, an AI-driven pharma tech company in the clinical-stage announced today that it has signed a partnership agreement with Bristol-Myers Squibb Company. Exscientia's portfolio of shared assets will benefit from this extended partnership and will contribute to Bristol Myers Squibb's drug pipeline. The partnership will use artificial intelligence to speed up the development of small molecule therapeutic drug candidates in a variety of therapeutic fields, including oncology and immu...

Read More
news image

ANGELINI PHARMA, INC. U.S. LAUNCHES FIRST INFECTION PREVENTION PORTFOLIO

PR Newswire | February 03, 2020

Angelini Pharma Inc. U.S., an international healthcare company headquartered in Maryland, is tackling the epidemic of healthcare-acquired infections (HAIs) with their new line of infection prevention products. HAIs continue to cause preventable complications and poor patient outcomes. HAIs cause more patient deaths every year than breast, prostate, and colorectal cancer. With Angelini's new portfolio, designed to be used across the care continuum, they are addressing the "why" behi...

Read More
news image

Pharma Tech

LEO PHARMA AND VEEVA SYSTEMS PARTNER FOR DIGITAL PATIENT-CENTERED TRIALS

LEO Pharma | September 30, 2021

LEO Pharma , a global leader in medical dermatology, and Veeva Systems announced a strategic technology partnership to enable scalable digital trials, paperless and patient-centered. Building on its success with the Veeva Clinical Operations suite, LEO Pharma will complete its standardization on existing Veeva clinical technology, be an early adopter of future Veeva solutions, and help shape the Veeva digital trials roadmap. By adopting technology and optimized business processes,...

Read More